Metformin increases cancer specific survival in colorectal cancer patients—National cohort study
ConclusionsColorectal cancer patients with T2DM treated with metformin as part of their diabetic therapy appear to have a superior OS and CS. However, prospective controlled studies are still needed to evaluate the efficacy of metformin as an anti-tumor agent.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Epidemiology | Fortamet | Health Insurance | Insurance | Lithuania Health | Metformin | Study